Drugs / SeeMore(TM)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00881075 | Jun 2008 → Mar 2012 | myocardial infarction | Eagle Vision Pharmaceutical Corp. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SeeMore(TM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00881075 ↗ |
| Modality | Diagnostic / imaging agent | “intravenous imaging agent for enhanced magnetic resonance imaging.” NCT00881075 ↗ |
| Route | Intravenous | “EVP 1001-1 will be administered intravenously over approximately one minute.” NCT00881075 ↗ |